lotilaner
Generic: LOTILANER·Brand: XDEMVY, Xdemvy
lotilaner: developed by 1 company · 1 clinical trial tracked.
lotilaner evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect lotilaner to TARS; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could lotilaner → TARS affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Ocular RosaceaRosaceaMeibomian Gland Dysfunction
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (4)
| Company | Phase |
|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) Ocular Rosacea | Approved |
| Tarsus Pharmaceuticals, Inc. (TARS) Ocular Rosacea | Phase 4 |
| Tarsus Pharmaceuticals, Inc. (TARS) Rosacea | Phase 4 |
| Tarsus Pharmaceuticals, Inc. (TARS) Meibomian Gland Dysfunction | Phase 4 |
Clinical Trials (1)
A Randomized, Vehicle-Controlled, Multicenter, Double-Masked, Parallel, Phase 2 Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of Lotilaner Ophthalmic Gel in Participants With Ocular Rosacea (KORE)
Primary endpoint: Incidence of Treatment Emergent Adverse Events
InterventionalRandomizedquadruple155 targetStarted 2025-12Completion 2027-122 sites · United StatesTarsus Pharmaceuticals, Inc.
Frequently asked questions
Who is developing lotilaner?
lotilaner is being developed by Tarsus Pharmaceuticals, Inc..
How many clinical trials involve lotilaner?
BioSniper tracks 1 clinical trial involving lotilaner.